Emedastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J1H7Y9OJV, chemically known as 1-methyl-4-(1-(2-ethoxyethyl)-1h-benzimidazo)-2-yl)(1,4)diazepane but generally known as emedastine, which bears US NIH Compound Identifier 3219. European Medicines Agency schedules Emedastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06503MIG. The term EMEDASTINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules emedastine in its Anatomical Therapeutic Chemical (ATC) Classification. EMEDASTINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule emedastine under HS 29339940 and SITC 51577. As of Q4 2014, EMEDASTINE remains the US FDA Preferred Term for this commodity. Emedastine bears US NLM identifiers UMLS ID C0064263 and NCI Concept Code C61743. SMILES: O(CCN1C(N2CCCN(CC2)C)NC2C1CCCC2)CC.